"posterior fossa group A (PFA) ependymoma"
"posterior fossa group B (PFB) ependymoma"
"supratentorial ependymoma, ZFTA fusion-positive"
Expected headings
"Classification"
"The unqualified term "ependymoma" should be used somewhat carefully as the entities included in this term vary in the literature and clinical practice. Generally, it is best to be specific, using the terminology of the WHO classification (see below). The five tumours included under the heading of "ependymal tumours" vary greatly in location, demographics, imaging features, histology, molecular characteristics, treatment and prognosis. They are, therefore, best thought of and discussed as separate entities."
"Ependymal tumours can occur anywhere within the neuraxis; however, the distribution, histology and molecular characteristics, including DNA methylation profiling, are fairly site-dependent. As such the 5th edition (2021) WHO classification divides ependymal tumours into five distinct entities; three based on location, further subdivided according to molecular characteristics, and two other specific entities 11,13,15,18."
"Ependymal tumours can occur anywhere within the neuraxis; however, the distribution, histology and molecular characteristics, including DNA methylation profiling, are fairly site-dependent. As such the 5th edition (2021) WHO classification divides ependymal tumours into five distinct entities; three based on location, further subdivided according to molecular characteristics, and two other specific entities 11,13,15,18."
"Ependymal tumours can occur anywhere within the neuraxis; however, the distribution, histology and molecular characteristics, including DNA methylation profiling, are fairly site-dependent. As such the 5th edition (2021) WHO classification divides ependymal tumours into five distinct entities; three based on location, further subdivided according to molecular characteristics, and two other specific entities 11,13,15,18."